ERBB3作为胶质母细胞瘤的治疗靶点：过表达可能会产生影响。
ERBB3 as a therapeutic target in glioblastoma: overexpression can make the difference.
作者信息
De Bacco Francesca, Boccaccio Carla
机构信息
Laboratory of Cancer Stem Cell Research, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy.
Department of Oncology, University of Torino Medical School, Turin, Italy.
出版信息
Mol Cell Oncol. 2021 Oct 27;8(5):1990677. doi: 10.1080/23723556.2021.1990677. eCollection 2021.
By exploiting an integrated experimental platform based on patient-derived cancer stem cells, we identified a glioblastoma subset characterized by inheritable Erb-B2 Receptor Tyrosine Kinase 3 (ERBB3) overexpression, metabolic dependency on ERBB3 signaling, and liability to ERBB3 targeting. We provide insights on why some glioblastomas may rely on ERBB3 and how to recognize them.
通过利用基于患者来源的癌症干细胞的综合实验平台，我们鉴定出了一个胶质母细胞瘤亚群，其特征为可遗传的表皮生长因子受体-2（ERBB3）过表达、对ERBB3信号传导的代谢依赖性以及对ERBB3靶向治疗的易感性。我们深入探讨了为何某些胶质母细胞瘤可能依赖ERBB3以及如何识别它们。
Zotero 插件